Amarin Corporation PLC Announces Notification of Patent Allowance for U.S. Application 13/623,450 Related to Vascepa® and FDA Approved MARINE Indication
Published: Dec 13, 2012
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of Notice of Allowance for U.S. Patent Application Serial Number 13/623,450. This application includes claims intended to protect the Vascepa® (icosapent ethyl) indication approved by the U.S. Food and Drug Administration (FDA) based on Amarin's MARINE clinical trial results.